

Provisional programme From biomarkers to clinical tests in psychiatry – the promise and the challenge 15-16 March 2015 Nice, France

Sunday 15 March 2015

17.00 – 17.15 Welcome and introduction by Shitij Kapur, UK, Chair of Biomarkers committee ECNP

17.15 – 17.45 Biomarkers in psychiatry – the holy grail a step closer?

Tom Insel, USA

17.45 – 19.30 The challenge and potential of biomarkers in psychiatry

Chair: Celso Arango, Spain

a. The scientific challenge
 b. The patient perspective
 c. The regulatory framework
 Roy Perlis, USA
 Paul Wicks, UK
 Karl Broich, Germany

19.30 - 20.00 Discussion

20.00 Dinner

Monday 16 March 2015

09.00 – 10.30 What success looks like and what happens next

Co-Chairs: Per Svenningson, Sweden & Gitte Knudsen, Denmark

a. MRI in MS
 b. Alzheimer's biomarkers
 c. Predicting conversion to psychosis
 Massimo Filippi, Italy
 Henrik Zetterberg, Sweden
 Paolo Fusar Poli,UK

10.30 - 10.45 Break

10:45-13.00 Biological markers/tests on their way to validation and implementation

Chair: Eduard Vieta, Spain

a. AssureRx
 b. AB Biotics - Neuropharmagen
 c. Qbtech
 d. Elminda
 e. Legal, policy and consumer implicn
 C. Anthony Altar, USA
 Jordi Espadaler, Spain
 Carl Reuterskiöld, Sweden
 Amit Reches, Israel
 Stuart Hogarth, UK

13.00 Lunch

13:45 Workshop – Panel discussion – Biomarkers in drug development

Moderator:

Panel discussants: David Collier, United Kingdom

Hartmuth Kolb, USA Birgird Sogaard, Denmark Will Spooren, Switzerland Johannes Tauscher, USA



14:45 Workshop – Panel discussion – Biomarkers as clinical tests

Moderator: Guy Goodwin, UK

Panel discussants: Michael O'Donovan, United Kingdom

Ali Mazaheri, the Netherlands Ilan Rabiner, United Kingdom Sabine Bahn, United Kingdom Nikoloas Koutsouleris, Germany

15.45 Lessons, next steps and ECNP by Shitij Kapur, UK, Chair Biomarkers Committee ECNP

16.00 Close